Microsoft Support Diagnostic Tool

Diadem to Discuss Biomarker Blood Tests for Alzheimer's Disease at TD Cowen Liquid Biopsy Summit

Retrieved on: 
Monday, December 4, 2023
Alzheimer's disease, Dementia, Patient, Spondyloarthropathy, Mandarin Oriental Hotel Group, Microsoft Support Diagnostic Tool, Diadem, Medical imaging, Pharmaceutical industry, Research

MILAN and NEW YORK , Dec. 4, 2023 /PRNewswire/ -- Diadem SpA, (Diadem), a company developing one of the first blood-based tests for the early and accurate prediction of clinical progression to Alzheimer's disease (AD), today announced that Chief Executive Officer Paul Kinnon will participate in the TD Cowen Liquid Biopsy Summit, to be held at the Mandarin Oriental Hotel in New York City on December 5, 2023. Mr. Kinnon will serve as a panelist on the Beyond Cancer Panel scheduled from 2:40-3:40 pm ET that day, which will be hosted by Daniel Brennan, Cowen Managing Director, Research, Health Care - Life Science & Diagnostic Tools.

Key Points: 
  • MILAN and NEW YORK , Dec. 4, 2023 /PRNewswire/ -- Diadem SpA, (Diadem), a company developing one of the first blood-based tests for the early and accurate prediction of clinical progression to Alzheimer's disease (AD), today announced that Chief Executive Officer Paul Kinnon will participate in the TD Cowen Liquid Biopsy Summit , to be held at the Mandarin Oriental Hotel in New York City on December 5, 2023.
  • Mr. Kinnon will serve as a panelist on the Beyond Cancer Panel scheduled from 2:40-3:40 pm ET that day, which will be hosted by Daniel Brennan, Cowen Managing Director, Research, Health Care - Life Science & Diagnostic Tools.
  • Mr. Kinnon noted, "It is gratifying to have the opportunity to participate in this TD Cowen conference highlighting critical advances in blood-based prognostic and diagnostic technologies.
  • We are excited about the potential of AlzoSure® Predict and other new approaches to help revolutionize the treatment of Alzheimer's and other dementias, by giving healthcare providers the tools to easily and cost-effectively determine whether patients are or are not at high risk of declining to AD in the coming years, by enabling drug developers to conduct more rapid and cost-effective clinical trials of new AD therapies and importantly, by ensuring the widest possible access as individuals and their families are able to obtain testing at home if they prefer."

VIPRE Q2 Email Security Report Reveals Malspam Attacks Up, News Sectors Targeted

Retrieved on: 
Tuesday, August 29, 2023
VIPRE, Organization, Industry Connections Security Group, BEC, Microsoft Support Diagnostic Tool, QR, Research, Privacy, Information technology, Microsoft Office, RCE, Mail, Sales, Online shopping, Q2

NEW YORK, Aug. 29, 2023 /PRNewswire/ -- VIPRE Security Group, a global leader and award-winning cybersecurity, privacy, and data protection company, today released its latest email-focused security research, "The VIPRE Q2 Email Security Report," a quarterly report that provides deep insights into the email threat landscape based on the analysis of nearly 2 billion emails.

Key Points: 
  • NEW YORK, Aug. 29, 2023 /PRNewswire/ -- VIPRE Security Group , a global leader and award-winning cybersecurity, privacy, and data protection company, today released its latest email-focused security research, "The VIPRE Q2 Email Security Report ," a quarterly report that provides deep insights into the email threat landscape based on the analysis of nearly 2 billion emails.
  • Specifically, according to VIPRE, 85% of phishing emails utilized malicious links in the content of the email, and spam emails increased by 30% from Q1 to Q2 2023.
  • Information technology organizations also overtook financial institutions (9%) as the most targeted sector for phishing in Q2 as compared to VIPRE's previous quarterly report.
  • The VIPRE research team has analyzed nearly 1.8 billion emails for the Q2 2023 email threat report, and collated the results in a comprehensive, accessible report to help organizations worldwide to tackle email security threats.

BTIG to Host Snowbird MedTech, Digital Health, Life Science and Diagnostic Tools Conference on February 14 - 16, 2023 – Firm Event to Attract Over 75 Industry-Leading and Emerging Healthcare Companies

Retrieved on: 
Tuesday, February 7, 2023
Research, Finance, Banking, Clinical Trials, Professional Services, Biotechnology, General Health, Health, Science, Other Science, Direct Corporate Access, Human, Microsoft Support Diagnostic Tool, CFA, Digital health, Conference, Medtech

BTIG announced today the “BTIG Snowbird MedTech, Digital Health, Life Science and Diagnostic Tools Conference” will take place on Tuesday, February 14through Thursday, February 16, 2023.

Key Points: 
  • BTIG announced today the “BTIG Snowbird MedTech, Digital Health, Life Science and Diagnostic Tools Conference” will take place on Tuesday, February 14through Thursday, February 16, 2023.
  • “The event provides a multi-day opportunity for industry leaders to make connections and explore emerging innovations and trends across the healthcare industry.”
    The BTIG Snowbird MedTech, Digital Health, Life Science and Diagnostic Tools Conference is an annual event held in Snowbird, Utah.
  • The event is resuming in-person meetings in 2023 after a three-year shift to virtual events in response to the pandemic.
  • BTIG’s Corporate Access program hosts client events across the consumer, energy and infrastructure, financials, healthcare, real estate and technology sectors.